Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

Vertical Research Upgrades Linde to Buy, Announces $330 Price Target

Vertical Research analyst Kevin McCarthy upgrades Linde (NYSE:LIN) from Hold to Buy and announces $330 price target.

byBenzinga Newsdesk

May 18, 2021

1 minute read

Vertical Research analyst Kevin McCarthy upgrades Linde (NYSE:LIN) from Hold to Buy and announces $330 price target.

HC Wainwright & Co. Maintains Buy on Evofem Biosciences, Lowers Price Target to $2.5

By Benzinga Newsdesk

Today, 9:19 PM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Evofem Biosciences (NASDAQ:EVFM) with a Buy and lowers the price target from $4 to $2.5.

EVFM

Looking Into Gossamer Bio’s Recent Short Interest

By Benzinga Insights

Today, 9:19 PM

Gossamer Bio's (NASDAQ:GOSS) short percent of float has fallen 32.89% since its last report. The company recently reported that it has 14.41 million shares sold short, which is 17.59% of all regular shares that are available for trading.

GOSS

Penny Stocks

ATE.TO: Pivoting to Acute Pain Relief for Otenaproxesul…

By Zacks Small Cap Research

Today, 9:19 PM

By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT

ATBPF

JP Morgan Upgrades Colgate-Palmolive to Overweight, Announces $79 Price Target

By Benzinga Newsdesk

Today, 9:19 PM

JP Morgan analyst Andrea Teixeira upgrades Colgate-Palmolive (NYSE:CL) from Neutral to Overweight and announces $79 price target.

Vertical Research Upgrades Linde to Buy, Announces $330 Price Target

Related Posts

HC Wainwright & Co. Maintains Buy on Evofem Biosciences, Lowers Price Target to $2.5

Looking Into Gossamer Bio’s Recent Short Interest

ATE.TO: Pivoting to Acute Pain Relief for Otenaproxesul…

JP Morgan Upgrades Colgate-Palmolive to Overweight, Announces $79 Price Target